<div id="readability-page-1"><p>Meyer Handelman Co. boosted its stake in  AbbVie Inc. (NYSE:ABBV - Free Report) by 3.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 169,964 shares of the company's stock after buying an additional 5,098 shares during the period. AbbVie makes up   1.2% of Meyer Handelman Co.'s portfolio, making the stock its 24th largest holding. Meyer Handelman Co.'s holdings in AbbVie were worth $39,353,000 as of its most recent filing with the SEC.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>Several other large investors have also recently bought and sold shares of ABBV. Norges Bank acquired a new position in shares of  AbbVie in the second quarter valued at approximately $4,288,200,000.  Laurel Wealth Advisors LLC boosted its stake in  AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period.  Assenagon Asset Management S.A. grew its holdings in  AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock valued at $804,116,000 after buying an additional 3,666,521 shares in the last quarter.  Vanguard Group Inc. increased its position in  AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after buying an additional 3,380,842 shares during the period.  Finally, Kingstone Capital Partners Texas LLC bought a new position in  AbbVie during the 2nd quarter worth $581,817,000. 70.23% of the stock is owned by institutional investors. </p><h2>AbbVie Trading Up 0.1%</h2><p>Shares of ABBV opened at $230.07 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $406.63 billion, a price-to-earnings ratio of 174.30, a PEG ratio of 1.31 and a beta of 0.36. The business's fifty day moving average is $226.73 and its 200-day moving average is $212.57. </p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie's revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  Equities analysts anticipate that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie's previous quarterly dividend of $1.64. AbbVie's dividend payout ratio  is 496.97%. </p><h2>Analyst Ratings Changes</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>ABBV has been the subject of a number of recent research reports. DZ Bank cut shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Erste Group Bank cut shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, October 14th. Citigroup cut their price objective on shares of AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, November 3rd. Raymond James Financial  set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. Finally, BMO Capital Markets lifted their price target on shares of AbbVie from $215.00 to $240.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday, September 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued  a Buy rating and eight have assigned  a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $245.84.</p><p><b>Check Out Our Latest Research Report on ABBV</b></p><h2>AbbVie Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AbbVie</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>The $650 Million Bet on AI's Future</li><li>Nvidia x 1,000,000</li><li>GOLD ALERT</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Meyer Handelman Co. increased its stake in AbbVie Inc. by 3.1% in Q3, owning 169,964 shares valued at $39.35 million. AbbVie represents 1.2% of Meyer Handelman's portfolio. Other investors like Norges Bank and Vanguard Group also hold significant shares. AbbVie's Q3 earnings exceeded estimates, with revenue up 9.1% year-over-year. The company raised its quarterly dividend to $1.73. Analysts have mixed ratings on AbbVie, with some downgrading their target prices.</p>

Meyer Handelman Co. Has $39.35 Million Stock Holdings in AbbVie Inc. $ABBV